In February, ViaCyte and Janssen Biotech announced the consolidation of the assets of Janssen BetaLogics group into ViaCyte, effectively combining the two leaders in the field of stem-cell-derived replacement therapies for type 1 diabetes.

ViaCyte also discussed preliminary results from the STEP ONE clinical trial of the company’s VC-01 product candidate — the first stem-cell-derived replacement therapy for the treatment of type 1 diabetes in clinical-stage development. The results demonstrated that the company is making progress translating the promising results observed in pre-clinical models to patients.

The news was covered internationally.  Read the articles by the Associated Press and Fortune.

Pin It on Pinterest